Gynaecology

Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

Retrieved on: 
Tuesday, April 9, 2024
Elevance Health, Anthem, Gynaecology, Risk assessment, Medicare, Woman, Medicare Advantage, Physician, Health insurance

Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California.

Key Points: 
  • Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California.
  • “We are very pleased to add Anthem Blue Cross to our list of payers providing coverage for our OvaSuite portfolio, which provides a clear benefit to physicians in their clinical assessment of women with adnexal masses,” said Torsten Hombeck, Chief Financial Officer of Aspira.
  • Our strategic focus on payer adoption continues to gather momentum.”
    Anthem is a leading health company dedicated to improving lives and communities.
  • Through its affiliated companies, Anthem serves more than 118 million people, including more than 45 million within its family of health plans.

Dr. Marra Francis Joins Genece Health as Chief Medical Officer

Retrieved on: 
Wednesday, April 3, 2024
Health, Obstetrics, Faculty, Gynaecology, Physician, FACOG, DEL, Memorial Hermann–Texas Medical Center, Lung, Breast, University, MD, Biology, Ovary, Cancer, Liquid biopsy, GeneDx, Occidental College

DEL MAR, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer detection for lung, breast, ovarian and other cancers, today announced that Marra Francis, MD, FACOG, has joined the company as its chief medical officer.

Key Points: 
  • DEL MAR, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer detection for lung, breast, ovarian and other cancers, today announced that Marra Francis, MD, FACOG, has joined the company as its chief medical officer.
  • Dr. Francis’ past experience also includes serving as head of medical affairs for women's health of Sema4 (now GeneDx); as executive medical director of EverlyWell; and as chief medical officer of Aspira Women's Health.
  • Dr. Francis holds a medical degree from the University of Connecticut Health Center and a bachelor of arts degree in biology from Occidental College.
  • “We are delighted to have Marra join our team at a very exciting time for Genece,” said Greg Gosch, CEO of Genece Heath.

Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, April 2, 2024
Uterus, Gynaecology, Longevity, Reproductive Sciences, Patient, Collaboration, University, EMA, MD, European Medicines Agency, European, PIPE, Esophageal atresia, Yale school, OTCQB, Cryptocurrency

The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.

Key Points: 
  • The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.
  • Company’s subsidiary in Hong Kong launched its longevity product business in Asia, generating more than $100,000 in 2023 sales.
  • Entered into securities purchase agreements with accredited investors for a $6 million private investment in public equity (PIPE) financing.
  • Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported fourth quarter and full year 2023 financial results.

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Ovarian cancer, California Department, Conference call, Conference, Development, MicroRNA, Artificiality, Patient, Travel, Cancer, Information technology, AUP, Society, Gynaecology, AACR, Poster, Medicare, Marketing, CMS, Human resources, Federal, Medi-Cal, Cryptocurrency

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements.
  • Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements.
  • Gross profit margin was 57.5% for the year ended December 31, 2023, compared to 52.8% for the year ended December 31, 2022.
  • Subsequent to the end of the quarter, Aspira raised $5.5 million in gross proceeds in a registered direct offering and concurrent private placement.

TGH Women's Institute Receives Highest Honor from National Accrediting Body

Retrieved on: 
Friday, April 5, 2024
Hospital, Mother, Midwifery, Tampa General Hospital, Obstetrics, Certification, Chair, Gynaecology, Joint Commission, Health, TGH, Patient, DNP, Accreditation, Infant, Pregnancy, Woman, MPH, Safety, Nursing care plan, Physician, Nursing

TAMPA, Fla., April 5, 2024 /PRNewswire/ -- The Women's Institute at Tampa General Hospital (TGH) announced that it has received the highest national designation (Level IV) in maternal care from The Joint Commission — the gold standard in accreditation — underscoring its commitment to excellence in care for mothers and babies.

Key Points: 
  • The Joint Commission, a nonprofit organization dedicated to empowering health care organizations in providing the highest level of safety and quality, verified the TGH Women's Institute as a Level IV Maternal Care hospital.
  • Founded in 1951, The Joint Commission is the nation's oldest and largest standards-setting and accrediting body in health care.
  • The TGH Women's Institute provides a full range of women's health services, from routine obstetrics and gynecology to more complex maternal-fetal medicine and neonatal care.
  • The Institute is one of only 11 health care facilities in Florida and the only one in Hillsborough County to receive this distinction.

Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call

Retrieved on: 
Monday, March 25, 2024
Gynaecology, Conference

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023, on Thursday, March 28, 2024.

Key Points: 
  • AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023, on Thursday, March 28, 2024.
  • Management will also host a conference call at an updated time of 8:30 am ET to discuss financial results and provide a corporate update.
  • Details for the call are as follows:
    Conference Call & Webcast Details:

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Flex, Growth, Urology, Communication, Patient, Telephone, Sale, TRUST, General surgery, Software, Security (finance), Motion, Freezing, LUNA, Surgeon, Bank statement, Gynaecology, Investment, Annual report, Triangle Park (Quezon City), GAAP, File, Optimism, FDA, CIS, Health, Nursing

“As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.

Key Points: 
  • “As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.
  • During the fourth quarter of 2023, the Company initiated five new Senhance Surgical System placements, one in Germany, one in Romania, two in the CIS region and one in Japan at Nagoya University Hospital.
  • In 2023, surgeons performed over 3,550 procedures utilizing the Senhance System, representing a 13% increase over the previous year.
  • In addition to regulatory milestones, the Company has introduced four Senhance System programs dedicated to pediatric departments in the U.S. and internationally.

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Retrieved on: 
Thursday, March 21, 2024
ART, Obstetrics, Fireside, Gynaecology, Infertility, Case Western Reserve University, IVF, Climate, University, Woman, Reproductive biology, FDA

Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference

Retrieved on: 
Thursday, March 21, 2024
Gynaecology, Conference

AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024.

Key Points: 
  • AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024.
  • Management will be available for one-on-one meetings with investors who are registered for the conference.

Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

Retrieved on: 
Monday, March 18, 2024
Georgetown University Law Center, Ovarian cancer, Development, Acceleration, California State University, Luminex Corporation, Information technology, Standard of care, Senior, Respiratory disease, University, Gynaecology, Woman, Doctor of Philosophy, Research and development, Endometriosis, Drug development, Dana–Farber Cancer Institute, Therapy, Amgen, DIA, Human resources, Medical device

AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President effective April 1, 2024. Dr. Milligan will report to Nicole Sandford, who will remain CEO. The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.

Key Points: 
  • The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.
  • She has demonstrated success in supporting pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health.
  • Dr. Milligan is a known and respected leader in women’s health who drives cross-functional strategies to achieve corporate success.
  • As President, Dr. Milligan will be a key member of the executive leadership team with direct responsibility for the Research and Development, Operations, Information Technology, and Human Resources functions.